Hoth Therapeutics Inc

NASDAQ:HOTH   3:07:48 PM EDT
1.09
+0.02 (+2.36%)
: $1.09 +0.01 (+0.46%)
Products, Regulatory

Hoth Therapeutics Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In Biolexa Clinical Trial

Published: 09/21/2021 14:39 GMT
Hoth Therapeutics Inc (HOTH) - Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in Biolexa Clinical Trial.
Hoth Therapeutics - Safety Review Committee Recommended That Study Proceed to Dosing Patients With Mild to Moderate Atopic Dermatitis.
Hoth Therapeutics - No Serious Adverse Events, No Drug-related Treatment-emergent Adverse Events Seen in Administration of Biolexa in Healthy Subjects.